Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ozanimod Tyramine Pressor Response Study
NCT04978298Phase 1Completed
- Sponsor
- Celgene Corporation
- Start
- Jul 2021
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ozanimod in multiple sclerosis (MS) and ulcerative colitis (UC) (5 arms), sponsored by Celgene Corporation. Primary endpoint: Tyramine Sensitivity Factor. Started Jul 2021; status: completed.
02
Drugs
ozanimod
03
Conditions
multiple sclerosis (MS)ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT04978298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04978298.